Olaparib + Durvalumab for Breast Cancer
(OlympiaN Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you stop using certain medications, specifically strong or moderate CYP3A inhibitors and inducers, before starting the study. There is a washout period (time without taking certain medications) of 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
What data supports the effectiveness of the drug combination Olaparib and Durvalumab for breast cancer?
Is the combination of Olaparib and Durvalumab safe for humans?
The combination of Olaparib and Durvalumab has been studied in various trials and is generally considered safe, with some patients experiencing side effects like immune-related reactions and fatigue. In one study, no dose-limiting toxicities were recorded, and the treatment was found to be tolerable.12367
How is the drug combination of Olaparib and Durvalumab unique for breast cancer treatment?
The combination of Olaparib and Durvalumab is unique because it combines a PARP inhibitor (Olaparib) with an immunotherapy drug (Durvalumab) to enhance antitumor activity, particularly in patients with BRCA-mutated breast cancer. This approach has shown improved response rates compared to standard chemotherapy, especially in certain high-risk subtypes of HER2-negative breast cancer.12378
What is the purpose of this trial?
This trial is testing olaparib alone and in combination with durvalumab for early-stage breast cancer patients with specific genetic markers. Olaparib stops cancer cells from repairing DNA, while durvalumab helps the immune system attack cancer. The goal is to find better treatment options for these patients.
Research Team
Anitra Fielding, MBChB
Principal Investigator
AstraZeneca
Eligibility Criteria
This trial is for adults over 18 with newly diagnosed, operable breast cancer that's not spread and has specific characteristics including a BRCA1 or BRCA2 mutation. Participants must be able to use contraception, provide consent, have good organ function, weigh at least 30 kg, and have an ECOG status of 0 or 1. Exclusions include those with certain heart conditions, active hepatitis or autoimmune diseases, HIV unless well-controlled on therapy, prior breast cancer treatments or exposure to certain drugs.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive olaparib monotherapy or olaparib plus durvalumab combination therapy as neoadjuvant treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for event-free survival and adverse events
Treatment Details
Interventions
- Durvalumab
- Olaparib
Durvalumab is already approved in European Union, United States, Japan for the following indications:
- Locally advanced, unresectable non-small cell lung cancer (NSCLC)
- Extensive-stage small cell lung cancer (ES-SCLC)
- Limited-stage small cell lung cancer (LS-SCLC)
- Locally advanced or metastatic urothelial carcinoma
- Not specified in provided sources
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology